Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Hodgkin Disease × Bendamustine Hydrochloride × Clear all

Phase

Phase 2 12 Phase 1/2 11 Phase 1 5 Phase 4 1 Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hodgkin Disease 1

Interventions

Brentuximab Vedotin 3 Vinblastine 2 Radiotherapy 2 Cyclophosphamide 2 tislelizumab 1 sintilimab 1 prednylidene 1 Watchful Waiting 1 Thiotepa 1 Prednisolone 1 Pentoxifylline 1 Filgrastim 1 Doxorubicin 1 Dacarbazine 1 Bendamustine Hydrochloride 1 Antilymphocyte Serum 1 ABVD protocol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06761911 2025-01-07

BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma

Dalian Medical University

Phase 4 Not yet recruiting

Hodgkin Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡